Enhertu Offers Better Overall Survival Than Kadcyla for Metastatic HER2-Positive Breast Cancer

2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than doubled the 12-month progression-free survival rate compared to Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated. At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla. Listen to the episode to hear Dr. Hurvitz explain: overall survival and progression-free survival results severe side effects of Enhertu how the researchers managed any severe lung problems that developed in people receiving Enhertu

Om Podcasten

Breastcancer.org is a nonprofit organization dedicated to providing the most reliable, complete, and up-to-date information about breast cancer. Our mission is to help women and their loved ones make sense of the complex medical and personal information about breast cancer, so they can make the best decisions for their lives. Breastcancer.org podcasts offer unique insights on prevention, treatment, research, and other breast cancer topics from our medical experts and invited guests.